Zacks: Brokerages Anticipate United Therapeutics Co. (UTHR) to Post $3.37 Earnings Per Share
Analysts expect United Therapeutics Co. (NASDAQ:UTHR) to post $3.37 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for United Therapeutics’ earnings. The highest EPS estimate is $4.34 and the lowest is $2.80. United Therapeutics posted earnings per share of $6.27 during the same quarter last year, which would indicate a negative year-over-year growth rate of 46.3%. The company is scheduled to announce its next earnings results on Wednesday, October 24th.
According to Zacks, analysts expect that United Therapeutics will report full-year earnings of $13.71 per share for the current fiscal year, with EPS estimates ranging from $12.66 to $15.00. For the next financial year, analysts forecast that the firm will report earnings of $11.14 per share, with EPS estimates ranging from $8.08 to $13.59. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million for the quarter, compared to analysts’ expectations of $368.63 million. During the same quarter last year, the company earned $4.37 EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year.
In other news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $119.00, for a total value of $96,390.00. Following the transaction, the director now owns 1,555 shares of the company’s stock, valued at $185,045. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Insiders sold 8,100 shares of company stock valued at $977,508 over the last quarter. Corporate insiders own 8.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. BancorpSouth Bank raised its position in shares of United Therapeutics by 11.4% in the second quarter. BancorpSouth Bank now owns 3,884 shares of the biotechnology company’s stock valued at $440,000 after purchasing an additional 397 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in United Therapeutics by 9.2% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,319 shares of the biotechnology company’s stock worth $602,000 after acquiring an additional 446 shares during the period. Retirement Systems of Alabama increased its position in United Therapeutics by 0.8% during the second quarter. Retirement Systems of Alabama now owns 56,385 shares of the biotechnology company’s stock worth $6,380,000 after acquiring an additional 462 shares during the period. Wedbush Securities Inc. increased its position in United Therapeutics by 13.5% during the second quarter. Wedbush Securities Inc. now owns 4,210 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 500 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in United Therapeutics by 5.6% during the first quarter. Thrivent Financial for Lutherans now owns 9,852 shares of the biotechnology company’s stock worth $1,107,000 after acquiring an additional 521 shares during the period. 95.85% of the stock is currently owned by institutional investors.
United Therapeutics stock opened at $124.52 on Tuesday. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 6.90, a P/E/G ratio of 27.85 and a beta of 1.24. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.35 and a current ratio of 4.64. United Therapeutics has a 52 week low of $100.57 and a 52 week high of $152.55.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.